New drug trial aims to shrink dangerous artery plaque
NCT ID NCT07303777
Summary
This study is testing whether an experimental drug called ABP-745 can reduce the amount of plaque buildup in the arteries of people with heart disease. Researchers will compare ABP-745 against a placebo in 200 participants over 52 weeks to see if it safely shrinks plaque. The goal is to better control the progression of atherosclerosis, which is a major cause of heart attacks and strokes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASCVD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Advara HeartCare Leabrook
Adelaide, Australia
Contact Email: •••••@•••••
Contact
-
Beijing Friendship Hospital, Capital Medical University
Beijing, China
-
Cardiovascular Institute of San Diego INC
San Diego, California, 91911, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Cardiovascular Research Foundation of Southern California
Beverly Hills, California, 90210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Cognivus
Wahroonga, Australia
Contact
-
Core Research Group Pty Ltd
Brisbane, Australia
Contact
-
Dalian Second Hospital
Dalian, China
Contact
-
Guangdong Province Hospital
Guangzhou, China
Contact
-
Huashan Hospital Fudan University
Shanghai, China
Contact
-
Jiangsu Province Hospital
Nanjing, China
Contact
-
Jinan Central Hospital
Jinan, China
Contact
-
Nanjing Drum Tower Hospital
Nanjing, China
Contact
-
NovaTrails
Newcastle, New South Wales, 2290, Australia
Contact
Contact Email: •••••@•••••
-
Peking Union Medical College Hospital
Beijing, China
Contact
-
Peking University First Hospital
Beijing, China
Contact
-
Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, China
Contact
-
Renmin Hospital of Wuhan University
Wuhan, China
Contact
-
Shaanxi Provincial People's Hospital
Xi'an, China
Contact
-
Shanghai General Hospital
Shanghai, China
Contact
-
Sir Run Run Shaw Hospital of Zhejiang University School of Medicine
Hangzhou, China
Contact
-
The Affiliated Hospital of Xuzhou Medical College
Xuzhou, China
Contact
-
The First Affiliated Hospital of Soochow University
Suzhou, China
Contact
-
The First Affiliated Hospital of Xian Jiaotong University
Xi'an, China
Contact
-
The First Affiliated Hospital of Zhejiang University school of medicine
Hangzhou, China
Contact
-
The Lundquist Institute
Torrance, California, 90502, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Second Affiliated Hospital of Xi'an Jiaotong University
Xi'an, China
Contact
-
The Zhongshan Hospital Affiliated to Fudan University
Shanghai, China
Contact
-
Tianjin General Hospital
Tianjin, China
Contact
-
University of the Sunshine Coast Clinical Trials Unit - Morayfield
Morayfield, Queensland, 4506, Australia
Contact
Contact
-
Washington University School of Medicine, St.louis
St Louis, Missouri, 63130, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Wuxi People's Hospital
Wuxi, China
Contact
-
Xuanwu Hospital Capital Medical University
Beijing, China
Contact
-
Zhejiang Provincial People's Hospital
Hangzhou, China
Contact
Conditions
Explore the condition pages connected to this study.